Answers are grounded in this paper and cite their sources.
Our case report describing the involution of EMN supports data from previous clinical trials indicating that combination BRAF and MEK inhibition may reduce cutaneous proliferative effects that arise on BRAF inhibitor monotherapy. Further studies are necessary to characterize the biological mechanisms underlying this phenomenon.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: